Results 131 to 140 of about 1,085,795 (289)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. [PDF]

BioDrugs, 2021
Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N.   +8 more
europepmc   +1 more source

Rapid, quantitative determination of aggregation and particle formation for antibody drug conjugate therapeutics with label-free Raman spectroscopy

, 2019
Chi Zhang, Jeremy S. Springall, Xiangyang Wang, Ishan Barman   +3 more
openalex   +2 more sources

Risk Factors for Anti-Infliximab Antibody Formation Among Patients with Inflammatory Bowel Disease

, 2023
Qusay Abdo, Mohammad Alnees, Razan Rabi, Ameer Kittaneh, Alaa Dweikat, Abdalaziz Darwish, Duha Najajra, Awwad Mahdi, Rajab Islam, Raghad Yaghmour   +9 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients. [PDF]

J Infect, 2022
Morales-Ortega A, Farfán-Sedano AI, Izquierdo-Martínez A, Llarena-Barroso C, Jaenes-Barrios B, Mesa-Plaza N, Toledano-Macías M, Soria Fernández-Llamazares G, Molina-Esteban L, García de Tena J, Prieto-Menchero S, Gonzalo-Pascua S, San Martín-López JV, Bernal-Bello D.   +13 more
europepmc   +1 more source

Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies

, 1996
Daniel Nyhan, Eric Lon Shampaine, Carol A. Hirshman, Robert G. Hamilton, Steven M. Frank, William A. Baumgartner, N. Franklin Adkinson   +6 more
openalex   +1 more source

Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis [PDF]

, 2017
Xiaodong Li, Michael S. Ominsky, Kelly S Villasenor, Qing‐Tian Niu, Frank Asuncion, Xuechun Xia, Mario Grisanti, Thomas J. Wronski, W. Scott Simonet, Hua Zhu Ke   +9 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. [PDF]

J Allergy Clin Immunol, 2021
Konnikova L, Robinson TO, Owings AH, Shirley JF, Davis E, Tang Y, Wall S, Li J, Hasan MH, Gharaibeh RZ, Mendoza Alvarez LB, Ryan LK, Doty A, Chovanec JF, O'Connell MP, Grunes DE, Daley WP, Mayer E, Chang L, Liu J, Snapper SB, Milner JD, Glover SC, Lyons JJ.   +23 more
europepmc   +1 more source